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While the antigens involved in the autoimmune
response can differ between MS patients—and even
change over time in an individual patient—the fact that
our approach was effective in different experimental
models shows this could act as a universal therapy.”
Abdolmohamad Rostami, MD, PhD

Oligodendrocyte forms
insulating myelin sheaths
around neuron axons.

Paradigm-Changing
Immunotherapy for
Multiple Sclerosis
In multiple sclerosis (MS), the body’s immune system
attacks the myelin sheath, the protective layer
surrounding nerve axons. Current MS therapies act
by suppressing the immune system broadly—with
sometimes serious side effects, including infection
and cancer. However, a team of researchers led
by Abdolmohamad Rostami, MD, PhD, professor
and chair of neurology, has found a way to prevent
immune cells from attacking myelin—while leaving the
rest of the immune system intact. In mouse models of
MS, their approach has halted disease progression.
“One of the biggest hurdles to stopping the attack
on the myelin sheath is that science doesn’t
know which component of myelin is triggering
the immune response in MS patients,” says Dr.
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Rostami. “Previous studies have tested the use
of single myelin antigens or combinations of
antigens to prevent autoimmunity, but those
methods have had limited clinical success.”
Dr. Rostami’s team took a different approach:
using oligodendrocytes, the type of cell that
produces the myelin sheath that wraps around
axons. Oligodendrocytes contain tiny sacs called
extracellular vesicles (EVs) that—the researchers
found—contain almost all the relevant myelin
antigens. The team harvested EVs from cultured
oligodendrocytes to create a therapy with the
potential to treat the disease without having to
know the exact identity of the effective antigen.

“We then injected the EVs intravenously in mice
that modeled different stages of MS,” Dr. Rostami
explains. “When administered before the disease
developed, the EVs had a prophylactic effect,
preventing the onset of symptoms like decreased
mobility and paralysis. When given after disease
onset, EVs significantly reduced severity of
symptoms.” Of particular note, the experimental
therapy only affected immune cells that were
attacking the myelin layer. The rest of the immune
system was intact and not weakened at all.
“While the antigens involved in the autoimmune
response can differ between MS patients—and
even change over time in an individual patient—the
fact that our approach was effective in different
experimental models shows this could act as a
universal therapy,” observes Dr. Rostami. “This is one
of several major advantages over current therapies.”
Working on a parallel research path, Dr. Rostami’s
team has also found that a compound of naturally
occurring elements may both reduce and help
reverse MS’s damage to the myelin sheaths covering
axons. “Although the evidence is preliminary, our
studies suggest that ursolic acid—a compound
found in the peels of fruits such as apples and
prunes, and some herbs—can both halt and repair
damage in animal models of disease,” says GuangXian Zhang, PhD, professor of neurology. The
researchers used a lab-grade purified form of ursolic
acid in a mouse model of MS that develops slowly,
mimicking human disease; and they began the
treatment at an advanced stage, when chronic tissue
damage had already affected the nervous system.
“After 20 days’ treatment, we began to see
improvement in the animals’ function; and after
60 days’ treatment, those that were initially
paralyzed had regained the ability to walk,
although with weakness,” Dr. Zhang explains.

Analyzing the mechanism for the improvement,
the investigators observed that ursolic acid
has two important effects: It suppressed
Th17 cells—immune cells that help drive the
pathological autoimmune response in MS—and
spurred maturation of oligodendrocytes, thus
enhancing the myelin sheath-making process.
“This maturation effect on oligodendrocytes is
crucial,” says Dr. Zhang. “In MS, myelin sheathmaking oligodendrocytes are depleted, and the
stem cells that produce new oligodendrocytes
are unable to mature. This compound helps
activate those stem cells and is likely responsible
for the reversal of symptoms we observed.”
Although ursolic acid is available as a dietary
supplement, it could be toxic at high doses. “A
number of tests are necessary to ascertain that this
compound is safe before initial clinical trials begin,”
says Dr. Rostami. “However, we are moving forward
quickly with this promising approach.” 
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